


Using **solid + liquid testing concurrently** in your practice

When looking to expand your patients’ options for targeted therapies, parallel testing of tumor tissue and liquid biopsy may provide a more comprehensive detection of actionable alterations than tissue or liquid biopsy testing alone. **Using xT and xF testing combined may offer insight into our patient’s cancer care throughout the course of disease.**

Provides a comprehensive patient view



A patient may have more gene alterations driving their cancer than a single biopsy can uncover. Data suggests that non-overlapping actionable gene alterations may be detected using concurrent tissue and liquid testing.^{1,2}

Provides a baseline for longitudinal testing

A patient’s tumor profile may change through the course of their disease. Published evidence supports the use of follow-up liquid biopsy NGS testing to uncover new gene alterations and resistance mechanisms prior to detection of the clinical or radiological progression.^{1,3,5} These variants may be missed when using tissue NGS testing due to sampling bias inherent in tissue biopsies.

Tempus makes it easy to implement concurrent testing in your practice.

- 1 Requisition form and online ordering allows you to select both xT and xF.
- 2 Blood drawn for xT tumor-normal match can also be used for xF test.
- 3 Mobile Phlebotomy services are available to assist patients who don’t have the ability to go into the clinic for the blood draw.

 **Learn more at tempus.com/genomic-profiling.**

Tempus offers a portfolio of smart genomic profiling tests to assess your patient.

xT Solid Tumor + Normal Test

Assay Type	Solid Tumor Tissue + Normal Match ⁵
Assay Overview	648 gene panel Whole transcriptome RNA seq with validated fusion detection
Immunotherapy Metrics	MSI Status Tumor Mutational Burden (TMB)

IHC Options: Mismatch Repair (MMR), PD-L1, 22C3, 28-8, SP142 clones

Add-on Tests: Tumor of Unknown Origin (TO), Homologous Recombination Deficiency (HRD)

xF Liquid Biopsy Test

Assay Type	Blood (ctDNA)
Assay Overview	105-DNA gene panel
Immunotherapy Metrics	MSI Status

1. Chae YK, Davis AA, Carneiro BA, et al. Oncotarget. 2016;7(40):65364-65373.
2. Aggarwal C, Thompson JC, Black TA et al. JAMA Oncol. 2019;5(2):173-180.
3. Parikh., et al. "Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers." Nature medicine 25.9 (2019)
4. Chae YK, Davis AA, Jain S et al. Mol Cancer Ther; 16(7)1412-1420.
5. Blood (saliva optional)